Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could predict cancer worsening in rare blood disorders

NCT ID NCT04942080

Knowledge-focused Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether changes in the level of a specific gene mutation (CALR) in the blood can help predict when certain blood cancers (myeloproliferative neoplasms) get worse. Researchers will collect blood samples from 260 adults diagnosed between 2006 and 2020 and track mutation levels over time. The goal is to see if these levels can serve as an early warning sign of disease progression, without testing any new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors use CALR mutation levels as a warning sign to detect disease worsening earlier in patients with certain blood cancers.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to any change in patient care, and results might not apply to all patients with these conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 260 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2021

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * adults (age ≥18 years), * affiliated to the national social security system, * with CALR mutated myeloproliferative neoplasm diagnosed between 2006 - 2020, * for which at least one sample is available at the time of diagnosis or before cytoreductive treatment, * who signed the consent to participate in the study, * included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM). Exclusion Criteria: * patient with another active hematological disease or cancer at the time of diagnosis, * person subject to legal protection scheme or incapable of giving consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential thrombocythemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cellular phase chronic idiopathic myelofibrosis essential thrombocythemia Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis thrombocytosis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Essential thrombocythemia Myeloproliferative neoplasm Primary myelofibrosis, fibrotic stage Primary myelofibrosis, prefibrotic stage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP Henri Mondor

    RECRUITING

    Paris, 94010, France

  • CHU Angers

    RECRUITING

    Angers, France

  • Ch Cholet

    RECRUITING

    Cholet, 49300, France

  • Ch Le Mans

    RECRUITING

    Le Mans, 72037, France

  • Ch Morlaix

    RECRUITING

    Morlaix, 29672, France

  • Ch Quimper

    RECRUITING

    Quimper, 29107, France

  • Chu Bordeaux

    RECRUITING

    Bordeaux, 33604, France

  • Chu Brest

    RECRUITING

    Brest, 29200, France

  • Chu Poitiers

    RECRUITING

    Poitiers, 86021, France

  • Chu Tours

    RECRUITING

    Tours, 37000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.